BAY-958
Product Specifications
UNSPSC Description
BAY-958 is a potent PTEFb/CDK9 inhibitor with high selectivity demonstrated in vitro, particularly within the CDK family. It shows strong antiproliferative activity against cancer cell lines such as HeLa and MOLM-13. In pharmacokinetic studies, BAY-958 exhibited good metabolic stability but had low aqueous solubility and moderate permeability, leading to challenges in bioavailability. Despite these limitations, BAY-958 hydrochloride effectively inhibited tumor growth in mouse xenograft models without significant toxicity, indicating promising efficacy in vivo. However, its suboptimal physicochemical properties prompted further development efforts to identify compounds with improved overall characteristics for potential clinical use[1].
Target Antigen
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
cancer
Assay Protocol
https://www.medchemexpress.com/bay-958.html
Smiles
O=S(CC1=CC=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=C1)(N)=O
Molecular Weight
389.40
References & Citations
[1]Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-121081/BAY-958-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-121081/
Clinical Information
No Development Reported
CAS Number
1335490-39-5
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
